Study of Options for Second-Line Effective Combination Therapy (SELECT)
- Conditions
- Health Condition 1: null- HIV-1 Infection
- Registration Number
- CTRI/2018/04/013128
- Lead Sponsor
- ational Institute of Health NIH AIDS Clinical Trials Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Closed to Recruitment of Participants
- Sex
- Not specified
- Target Recruitment
- 0
HIV-1 infected
Confirmation of first-line virologic failure
Certain laboratory values obtained within 45 days prior to study entry, •Negative pregnancy test within 48 hours prior to study entry.
1 Use of any immunomodulator, HIV vaccine, or other investigational therapy within 45 days prior to study entry, with the exception of a tapering course of corticosteroids as acute therapy for pneumocystis jiroveci pneumonia (PCP) or acute asthma/chronic obstructive pulmonary disease flare and/or prednisone at a daily dose of 10 mg (physiologic replacement dose)
2 If the potential participant has had resistance testing, evidence of broad NRTI cross-resistance that,
3 in the opinion of the investigator, would not allow selection of an effective NRTI combination if the participant were randomized to the LPV/r + best available NRTIs arm
4 Prior exposure to a Protease Inhibitor
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method